Dysregulation of sphingolipid metabolism in cancer
Altered sphingolipid metabolism contributes to cancer progression and presents an exploitable target for the development of novel chemotherapeutics. Bioactive sphingolipid metabolites also have the potential to serve as vital biomarkers for cancer and be utilized to determine disease progression, as...
Gespeichert in:
| Veröffentlicht in: | Cancer biology & therapy 2011-01, Vol.11 (2), p.138-149 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 149 |
|---|---|
| container_issue | 2 |
| container_start_page | 138 |
| container_title | Cancer biology & therapy |
| container_volume | 11 |
| creator | Ryland, Lindsay K. Fox, Todd E. Liu, Xin Loughran, Thomas P. Kester, Mark |
| description | Altered sphingolipid metabolism contributes to cancer progression and presents an exploitable target for the development of novel chemotherapeutics. Bioactive sphingolipid metabolites also have the potential to serve as vital biomarkers for cancer and be utilized to determine disease progression, as well as guide therapeutic regimens. Moreover, identification of these sphingolipid biomarkers is achievable based on recent technological advances in sphingolipidomics, which have aided in detection of sphingolipid metabolites through tools like mass spectrometry. Excellent reviews have previously focused on the biochemical role that sphingolipids have in cancer pathogenesis and treatment. The aim of this review is to concentrate on the critical metabolites and enzymes that contribute to the dysregulation in sphingolipid metabolism, and highlight relevant translational research that is directed towards novel therapies. |
| doi_str_mv | 10.4161/cbt.11.2.14624 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_21209555</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>847434109</sourcerecordid><originalsourceid>FETCH-LOGICAL-c536t-f9090dd10cf918bb07edf704ad5b9b076435015cfde773ae6218a9df625ba1e23</originalsourceid><addsrcrecordid>eNqFkEtPxCAUhYnR-N66NN25auVSaMtSx2diYmJ0TSiPEdOWCp2Y-fcyMzo744pL-M65nIPQGeCCQgWXqp0KgIIUQCtCd9AhMMbyhtXV7moum5xiWh-goxg_MCY1qfg-OiBAME_gISI3yxjMfNHJyfkh8zaL47sb5r5zo9NZbybZpjn2mRsyJQdlwgnas7KL5vTnPEZvd7evs4f86fn-cXb1lCtWVlNuOeZYa8DKcmjaFtdG2xpTqVnL062iJcPAlNWmrktpKgKN5NpWhLUSDCmP0cXGdwz-c2HiJHoXlek6ORi_iKKhNS0pYJ7IYkOq4GOKY8UYXC_DUgAWq5pEqkkACCLWNSXB-Y_1ou2N3uK_vSQANkBapk1snY_KmZR-i64cZZic6szWtPxHg8nLcvU4u35df2bUNqn4RuUG60Mvv3zotJjksvPBhlS4i6L8I8Y3eq6bRA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>847434109</pqid></control><display><type>article</type><title>Dysregulation of sphingolipid metabolism in cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Ryland, Lindsay K. ; Fox, Todd E. ; Liu, Xin ; Loughran, Thomas P. ; Kester, Mark</creator><creatorcontrib>Ryland, Lindsay K. ; Fox, Todd E. ; Liu, Xin ; Loughran, Thomas P. ; Kester, Mark</creatorcontrib><description>Altered sphingolipid metabolism contributes to cancer progression and presents an exploitable target for the development of novel chemotherapeutics. Bioactive sphingolipid metabolites also have the potential to serve as vital biomarkers for cancer and be utilized to determine disease progression, as well as guide therapeutic regimens. Moreover, identification of these sphingolipid biomarkers is achievable based on recent technological advances in sphingolipidomics, which have aided in detection of sphingolipid metabolites through tools like mass spectrometry. Excellent reviews have previously focused on the biochemical role that sphingolipids have in cancer pathogenesis and treatment. The aim of this review is to concentrate on the critical metabolites and enzymes that contribute to the dysregulation in sphingolipid metabolism, and highlight relevant translational research that is directed towards novel therapies.</description><identifier>ISSN: 1538-4047</identifier><identifier>EISSN: 1555-8576</identifier><identifier>DOI: 10.4161/cbt.11.2.14624</identifier><identifier>PMID: 21209555</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Antineoplastic Agents - metabolism ; Antineoplastic Agents - therapeutic use ; Binding ; Biology ; Bioscience ; Calcium ; Cancer ; Cell ; Cycle ; Forecasting ; Humans ; Landes ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Neoplasms - therapy ; Organogenesis ; Proteins ; Sphingolipids - chemistry ; Sphingolipids - metabolism ; Sphingolipids - physiology</subject><ispartof>Cancer biology & therapy, 2011-01, Vol.11 (2), p.138-149</ispartof><rights>Copyright © 2011 Landes Bioscience 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c536t-f9090dd10cf918bb07edf704ad5b9b076435015cfde773ae6218a9df625ba1e23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21209555$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ryland, Lindsay K.</creatorcontrib><creatorcontrib>Fox, Todd E.</creatorcontrib><creatorcontrib>Liu, Xin</creatorcontrib><creatorcontrib>Loughran, Thomas P.</creatorcontrib><creatorcontrib>Kester, Mark</creatorcontrib><title>Dysregulation of sphingolipid metabolism in cancer</title><title>Cancer biology & therapy</title><addtitle>Cancer Biol Ther</addtitle><description>Altered sphingolipid metabolism contributes to cancer progression and presents an exploitable target for the development of novel chemotherapeutics. Bioactive sphingolipid metabolites also have the potential to serve as vital biomarkers for cancer and be utilized to determine disease progression, as well as guide therapeutic regimens. Moreover, identification of these sphingolipid biomarkers is achievable based on recent technological advances in sphingolipidomics, which have aided in detection of sphingolipid metabolites through tools like mass spectrometry. Excellent reviews have previously focused on the biochemical role that sphingolipids have in cancer pathogenesis and treatment. The aim of this review is to concentrate on the critical metabolites and enzymes that contribute to the dysregulation in sphingolipid metabolism, and highlight relevant translational research that is directed towards novel therapies.</description><subject>Antineoplastic Agents - metabolism</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Binding</subject><subject>Biology</subject><subject>Bioscience</subject><subject>Calcium</subject><subject>Cancer</subject><subject>Cell</subject><subject>Cycle</subject><subject>Forecasting</subject><subject>Humans</subject><subject>Landes</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Neoplasms - therapy</subject><subject>Organogenesis</subject><subject>Proteins</subject><subject>Sphingolipids - chemistry</subject><subject>Sphingolipids - metabolism</subject><subject>Sphingolipids - physiology</subject><issn>1538-4047</issn><issn>1555-8576</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><recordid>eNqFkEtPxCAUhYnR-N66NN25auVSaMtSx2diYmJ0TSiPEdOWCp2Y-fcyMzo744pL-M65nIPQGeCCQgWXqp0KgIIUQCtCd9AhMMbyhtXV7moum5xiWh-goxg_MCY1qfg-OiBAME_gISI3yxjMfNHJyfkh8zaL47sb5r5zo9NZbybZpjn2mRsyJQdlwgnas7KL5vTnPEZvd7evs4f86fn-cXb1lCtWVlNuOeZYa8DKcmjaFtdG2xpTqVnL062iJcPAlNWmrktpKgKN5NpWhLUSDCmP0cXGdwz-c2HiJHoXlek6ORi_iKKhNS0pYJ7IYkOq4GOKY8UYXC_DUgAWq5pEqkkACCLWNSXB-Y_1ou2N3uK_vSQANkBapk1snY_KmZR-i64cZZic6szWtPxHg8nLcvU4u35df2bUNqn4RuUG60Mvv3zotJjksvPBhlS4i6L8I8Y3eq6bRA</recordid><startdate>20110115</startdate><enddate>20110115</enddate><creator>Ryland, Lindsay K.</creator><creator>Fox, Todd E.</creator><creator>Liu, Xin</creator><creator>Loughran, Thomas P.</creator><creator>Kester, Mark</creator><general>Taylor & Francis</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110115</creationdate><title>Dysregulation of sphingolipid metabolism in cancer</title><author>Ryland, Lindsay K. ; Fox, Todd E. ; Liu, Xin ; Loughran, Thomas P. ; Kester, Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c536t-f9090dd10cf918bb07edf704ad5b9b076435015cfde773ae6218a9df625ba1e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antineoplastic Agents - metabolism</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Binding</topic><topic>Biology</topic><topic>Bioscience</topic><topic>Calcium</topic><topic>Cancer</topic><topic>Cell</topic><topic>Cycle</topic><topic>Forecasting</topic><topic>Humans</topic><topic>Landes</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Neoplasms - therapy</topic><topic>Organogenesis</topic><topic>Proteins</topic><topic>Sphingolipids - chemistry</topic><topic>Sphingolipids - metabolism</topic><topic>Sphingolipids - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ryland, Lindsay K.</creatorcontrib><creatorcontrib>Fox, Todd E.</creatorcontrib><creatorcontrib>Liu, Xin</creatorcontrib><creatorcontrib>Loughran, Thomas P.</creatorcontrib><creatorcontrib>Kester, Mark</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer biology & therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ryland, Lindsay K.</au><au>Fox, Todd E.</au><au>Liu, Xin</au><au>Loughran, Thomas P.</au><au>Kester, Mark</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dysregulation of sphingolipid metabolism in cancer</atitle><jtitle>Cancer biology & therapy</jtitle><addtitle>Cancer Biol Ther</addtitle><date>2011-01-15</date><risdate>2011</risdate><volume>11</volume><issue>2</issue><spage>138</spage><epage>149</epage><pages>138-149</pages><issn>1538-4047</issn><eissn>1555-8576</eissn><abstract>Altered sphingolipid metabolism contributes to cancer progression and presents an exploitable target for the development of novel chemotherapeutics. Bioactive sphingolipid metabolites also have the potential to serve as vital biomarkers for cancer and be utilized to determine disease progression, as well as guide therapeutic regimens. Moreover, identification of these sphingolipid biomarkers is achievable based on recent technological advances in sphingolipidomics, which have aided in detection of sphingolipid metabolites through tools like mass spectrometry. Excellent reviews have previously focused on the biochemical role that sphingolipids have in cancer pathogenesis and treatment. The aim of this review is to concentrate on the critical metabolites and enzymes that contribute to the dysregulation in sphingolipid metabolism, and highlight relevant translational research that is directed towards novel therapies.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>21209555</pmid><doi>10.4161/cbt.11.2.14624</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1538-4047 |
| ispartof | Cancer biology & therapy, 2011-01, Vol.11 (2), p.138-149 |
| issn | 1538-4047 1555-8576 |
| language | eng |
| recordid | cdi_pubmed_primary_21209555 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Antineoplastic Agents - metabolism Antineoplastic Agents - therapeutic use Binding Biology Bioscience Calcium Cancer Cell Cycle Forecasting Humans Landes Neoplasms - drug therapy Neoplasms - metabolism Neoplasms - therapy Organogenesis Proteins Sphingolipids - chemistry Sphingolipids - metabolism Sphingolipids - physiology |
| title | Dysregulation of sphingolipid metabolism in cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T23%3A58%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dysregulation%20of%20sphingolipid%20metabolism%20in%20cancer&rft.jtitle=Cancer%20biology%20&%20therapy&rft.au=Ryland,%20Lindsay%20K.&rft.date=2011-01-15&rft.volume=11&rft.issue=2&rft.spage=138&rft.epage=149&rft.pages=138-149&rft.issn=1538-4047&rft.eissn=1555-8576&rft_id=info:doi/10.4161/cbt.11.2.14624&rft_dat=%3Cproquest_pubme%3E847434109%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=847434109&rft_id=info:pmid/21209555&rfr_iscdi=true |